Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000671677 | SCV000796676 | likely pathogenic | Bardet-Biedl syndrome 12 | 2017-12-28 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001058016 | SCV001222551 | pathogenic | Bardet-Biedl syndrome | 2022-07-05 | criteria provided, single submitter | clinical testing | This variant disrupts a region of the BBS12 protein in which other variant(s) (p.Arg675*) have been determined to be pathogenic (PMID: 20827784, 21642631). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 555788). This variant has not been reported in the literature in individuals affected with BBS12-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gln443Cysfs*22) in the BBS12 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 268 amino acid(s) of the BBS12 protein. |